Floatz logo

Dexdomitor

Parkinson Disease

Vanderbilt UniversitySmall moleculePhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

241 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Istradefylline
Georgetown University
Phase 4BBB
Rasagiline
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Pardoprunox
Abbott Products
Phase 3BBB

View all 50 →

Same molecule, other indications

Dexdomitor is also rated in:

dystonic disorderDormant
B
Indicative · Phase 2/3
57 / 100
View asset →
schizoaffective disorderDormant
CC
Indicative · Phase 1
44 / 100
View asset →
schizophreniaDormant
CC
Indicative · Phase 1
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →